Skin prebiotic composition comprising glycerol and disaccharides

A skin prebiotic composition with glycerol and disaccharides addresses the imbalance in skin microbiota by promoting Staphylococcus epidermidis growth and inhibiting Cutibacterium acnes, enhancing skin health and reducing acne and sebum production.

KR103044925B1Active Publication Date: 2026-11-10COSMAX INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
KR1020240089111
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-07-05
Publication Date
2026-11-10
Estimated Expiration
2044-07-05

AI Technical Summary

Technical Problem

There is a need to develop compositions that induce balance in the skin microbiome to prevent or treat skin diseases associated with disrupted microbial communities, particularly focusing on the growth of beneficial bacteria like Staphylococcus epidermidis while inhibiting acne-causing bacteria such as Cutibacterium acnes.

Method used

A skin prebiotic composition comprising glycerol and one or more disaccharides, specifically lactose, sucrose, and maltose, is formulated to promote the growth of Staphylococcus epidermidis while inhibiting Cutibacterium acnes, thereby restoring a healthy balance of skin microbiota.

Benefits of technology

The composition effectively increases the relative abundance of Staphylococcus epidermidis, generates microcurrents, and reduces acne and sebum production, improving skin health and balance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024073352572-PAT00002_ABST
    Figure 112024073352572-PAT00002_ABST
Patent Text Reader

Abstract

The present invention relates to a skin prebiotic composition comprising glycerol and disaccharides, wherein the composition has an excellent skin improvement effect by inducing a balance of the microbiome within the skin through optimizing the content of glycerol and disaccharides.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] This relates to a skin prebiotic composition. Background Technology

[0002] The skin's ecosystem provides diverse habitats for microorganisms, and a wide range of microbes inhabit it. Humans, as hosts, form a symbiotic relationship with these microbes, which are known to exert many positive effects on the host. Generally, the skin is cold, acidic, and remains dry. Structurally, the epidermis forms the skin barrier, playing a crucial role in blocking the penetration of microorganisms and toxins while retaining moisture. The uppermost layer of the epidermis consists of the stratum corneum.

[0003] The skin microbiome refers to the community of microorganisms inhabiting the skin, which plays an important role in maintaining skin health and balance; if the balance of the microbial community on normal skin is disrupted, various skin diseases may occur.

[0004] Therefore, there is a need to develop new compositions that induce balance in the skin microbiome. The problem to be solved

[0005] One aspect provides a skin prebiotic composition comprising glycerol; and one or more disaccharides selected from the group consisting of lactose, sucrose, and maltose.

[0006] Another aspect provides a cosmetic composition comprising the above-mentioned prebiotic composition.

[0007] Another aspect provides a topical skin composition comprising the above-mentioned skin prebiotic composition.

[0008] Another aspect provides a pharmaceutical composition for the prevention or treatment of diseases associated with increased skin sebum production, comprising a prebiotic composition.

[0010] Other objects and advantages of this application will become more apparent from the following detailed description, together with the appended claims and drawings. Anything not described in this specification is omitted, as it can be sufficiently recognized and inferred by those skilled in the art of this application or a similar art field. means of solving the problem

[0011] Each description and embodiment disclosed in this application may be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application should not be considered limited by the specific descriptions provided below.

[0012] One aspect provides a skin prebiotic composition comprising glycerol; and one or more disaccharides selected from the group consisting of lactose, sucrose, and maltose.

[0013] In one experimental example, Staphylococcus epidermidis ( Staphylococcus epidermidis While inducing the growth of ) the acne bacteria Cutibacterium acnes ( Cutibacterium acnes We intended to identify saccharides that inhibit the growth of ). As a result, it was confirmed that disaccharides, specifically lactose, sucrose, and maltose, induced the growth of Staphylococcus epidermidis while maintaining or inhibiting the growth of Cutibacterium acnes.

[0014] In this specification, the term “prebiotics” refers to a food that induces the growth of beneficial bacteria, and “skin prebiotics” may refer to a food that induces the growth of beneficial bacteria among skin-derived strains. Accordingly, a “skin prebiotic composition” may be a composition containing a food that induces the growth of beneficial skin bacteria.

[0015] The above composition may include glycerol, lactose, and sucrose.

[0016] The weight ratio of glycerol and disaccharides in the above composition is 2:1 to 100:1, 2:1 to 90:1, 2:1 to 80:1, 2:1 to 70:1, 2:1 to 60:1, 2:1 to 50:1, 2:1 to 40:1, 2:1 to 35:1, 5:1 to 100:1, 5:1 to 90:1, 5:1 to 80:1, 5:1 to 70:1, 5:1 to 60:1, 5:1 to 50:1, 5:1 to 40:1, 5:1 to 35:1, 10:1 to 100:1, 10:1 to 90:1, 10:1 to 80:1, 10:1 to 70:1, 10:1 to 60:1, 10:1 to 50:1, 10:1 to 40:1, 10:1 to 35:1, 15:1 to 100:1, 15:1 to 90:1, 15:1 to 80:1, 15:1 to 70:1, 15:1 to 60:1, 15:1 to 50:1, 15:1 to 40:1, 15:1 to 35:1, 20:1 to 100:1, 20:1 to 90:1, 20:1 to 80:1, 20:1 to 70:1, 20:1 to 60:1, 20:1 to 50:1, 20:1 to 40:1, 20:1 to 35:1, 25:1 to It may be 100:1, 25:1 to 90:1, 25:1 to 80:1, 25:1 to 70:1, 25:1 to 60:1, 25:1 to 50:1, 25:1 to 40:1, 25:1 to 35:1, 30:1 to 100:1, 30:1 to 90:1, 30:1 to 80:1, 30:1 to 70:1, 30:1 to 60:1, 30:1 to 50:1, 30:1 to 40:1, or 30:1 to 35:1. For example, it may be 34.33:1.More specifically, the weight ratio of glycerol, lactose, and sucrose in the above composition may be 5 to 200: 1 to 10: 1 to 10, 5 to 200: 1 to 5: 1 to 5, 5 to 100: 1 to 10: 1 to 10, 5 to 100: 1 to 5: 1 to 5, 50 to 100: 1 to 10: 1 to 10, or 50 to 100: 1 to 5: 1 to 5. For example, it may be 69:1:1.

[0017] If outside the above range, the prebiotic composition is Staphylococcus epidermidis ( Staphylococcus epidermidis While sufficiently inducing the growth of ) while Cutibacterium acnes ( Cutibacterium acnes The growth of ) may not be sufficiently inhibited or suppressed, and thus may not induce a healthy balance of microbiota within the skin.

[0018] In this specification, the term “skin flora” may be used interchangeably with “skin microbiome” and may refer to a community of microorganisms living on the skin. The balance of skin flora plays an important role in maintaining the health and balance of the skin, and if the balance of the microbial community inhabiting normal skin is disrupted, various skin diseases may occur.

[0019] In this specification, the term “growth” may be used interchangeably with “activity,” “growth,” and “proliferation,” and specifically refers to increasing the number of strains within the skin.

[0020] According to one experimental example, a skin prebiotic composition may induce a balance of the skin flora by including glycerol and disaccharides in an appropriate weight ratio to induce the growth of Staphylococcus epidermidis while inhibiting the growth of Cutibacterium acnes, thereby increasing the relative abundance of Staphylococcus epidermidis in the skin.

[0022] Staphylococcus epidermidis is a Gram-positive bacterium that typically inhabits the skin and can generate microcurrents. Staphylococcus epidermidis generates microcurrents by releasing electrons produced during the metabolism of carbon-rich carbohydrates out of the cell.

[0023] The above composition is Staphylococcus epidermidis ( Staphylococcus epidermidis It may generate a microcurrent.

[0024] According to one experimental example, the balance of the microbiota in the skin can appropriately induce the growth of Staphylococcus epidermidis to generate microcurrents, thereby inhibiting the growth of Cutibacterium acnes.

[0026] Another aspect provides a cosmetic composition comprising the above-mentioned prebiotic composition. In the above-mentioned cosmetic composition, the terms and elements mentioned that are identical to those already mentioned are as described above.

[0027] The above composition may be used to improve skin condition.

[0028] The above skin condition improvement may be improvement of acne, improvement of sebum secretion, or a combination thereof.

[0029] In this specification, the term “acne” refers to Cutibacterium acnes ( Cutibacterium acnes It may be due to ), and acne improvement may specifically be a decrease in the number of open and closed comedones.

[0030] In this specification, the term "improvement" may mean any action that at least reduces parameters related to the alleviation or treatment of a condition, such as the degree of symptoms.

[0031] In one embodiment, the composition is present in an amount of 0.001 wt% to 80 wt% based on the total weight of the cosmetic composition, for example, 0.01 wt% to 60 wt%, 0.01 wt% to 40 wt%, 0.01 wt% to 30 wt%, 0.01 wt% to 20 wt%, 0.01 wt% to 10 wt%, 0.01 wt% to 5 wt%, 0.05 wt% to 60 wt%, 0.05 wt% to 40 wt%, 0.05 wt% to 30 wt%, 0.05 wt% to 20 wt%, 0.05 wt% to 10 wt%, 0.05 wt% to 5 wt%, 0.1 wt% to 60 wt%, 0.1 wt% to 40 wt%, 0.1 wt% to 30 wt%, 0.1 wt% It may be included in an amount of up to 20 weight%, 0.1 weight% to 10 weight%, 0.1 weight% to 5 weight%, 0.1 weight% to 3 weight%, and 0.1 weight% to 2 weight%.

[0032] The above cosmetic composition may have, for example, a softening lotion, a nourishing lotion, a massage cream, a nourishing cream, an essence, a pack, a patch, a mask sheet, a gel, an ointment, an ampoule, or a cosmetic formulation of a skin-adhesive type.

[0033] The ingredients included in the above cosmetic composition may include ingredients commonly used in cosmetic compositions in addition to the above composition as active ingredients, and may include, for example, conventional auxiliary agents and carriers such as stabilizers, solubilizers, vitamins, pigments, and fragrances.

[0035] Another aspect provides a topical skin composition comprising the above-mentioned skin prebiotic composition. In the topical skin composition, the terms and elements mentioned are identical to those already mentioned.

[0036] The above topical skin preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, drug-containing bandage, lotion, or a combination thereof.

[0037] The above-mentioned topical preparation may be appropriately formulated with ingredients commonly used in topical preparations for the skin, such as cosmetics or pharmaceuticals, for example, aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, UV absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, or combinations thereof as needed. The above-mentioned topical preparation may also appropriately formulate metal chelating agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid; caffeine, tannins, bellapamil, licorice extract, glablidin, various herbal medicines; pharmaceuticals such as tocopherol acetate, glycyrrhizic acid, tranexamic acid and its derivatives or salts thereof; vitamin C, magnesium ascorbate phosphate, ascorbate glucoside, arbutin, or kojic acid.

[0038] In one embodiment, the composition is present in an amount of 0.001 wt% to 80 wt%, for example, 0.01 wt% to 60 wt%, 0.01 wt% to 40 wt%, 0.01 wt% to 30 wt%, 0.01 wt% to 20 wt%, 0.01 wt% to 10 wt%, 0.01 wt% to 5 wt%, 0.05 wt% to 60 wt%, 0.05 wt% to 40 wt%, 0.05 wt% to 30 wt%, 0.05 wt% to 20 wt%, 0.05 wt% to 10 wt%, 0.05 wt% to 5 wt%, 0.1 wt% to 60 wt%, 0.1 wt% to 40 wt%, 0.1 wt% to 30 wt%, 0.1 wt%. It may be included in weight% to 20 weight%, 0.1 weight% to 10 weight%, 0.1 weight% to 5 weight%, 0.1 weight% to 3 weight%, and 0.1 weight% to 2 weight%.

[0040] Another aspect provides a pharmaceutical composition for the prevention or treatment of diseases associated with increased skin sebum production, comprising a prebiotic composition. In the pharmaceutical composition, the terms and elements mentioned are identical to those already mentioned.

[0041] In this specification, the term "prevention" refers to any act in which the possibility of the onset of skin-related diseases is suppressed or delayed by the administration of the composition of the present invention.

[0042] In this specification, the term "treatment" refers to any act of improving or beneficially altering the symptoms of a skin-related disease by administering a composition of the present invention.

[0043] The conditions associated with the above-mentioned increase in skin sebum may be acne, seborrheic dermatitis, or folliculitis.

[0044] The above pharmaceutical composition may additionally comprise a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, and the lubricant may be magnesium stearate, talc, or a combination thereof. The carrier may be an excipient, a disintegrant, a binder, a lubricant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be calcium carboxymethylcellulose, sodium starch glycolate, calcium anhydrous phosphate, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.

[0045] The above pharmaceutical composition may be formulated into an oral or parenteral administration formulation. The oral administration formulation may be a granule, powder, liquid, tablet, capsule, dry syrup, or a combination thereof. The parenteral administration formulation may be an injection.

[0047] Additionally, another aspect provides a method for preventing, improving, or treating a condition of an individual comprising the step of treating or administering an effective amount of the above-described composition to an individual in need thereof. The condition of the individual may be a condition related to the skin or a condition related to sebum secretion.

[0048] The above prebiotics may be administered in combination with probiotics. Specifically, the prebiotics may be administered simultaneously, separately, or sequentially.

[0049] The terms “administering,” “introducing,” and “implanting” are used interchangeably and may mean the placement of a composition according to one embodiment into an individual by a method or route resulting in at least partial localization of the composition according to one embodiment to a desired site.

[0050] Administration may be performed by methods known in the art. Administration may be performed directly to an individual by any means, via routes such as, for example, intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal, or subcutaneous administration. The administration may be performed systemically or locally.

[0051] The above-mentioned individual may be a mammal, for example, a human, cattle, horses, pigs, dogs, sheep, goats, or cats. The above-mentioned individual may be an individual requiring an effect of improving skin condition, for example, improving acne, improving sebum secretion, or a combination thereof.

[0052] The above administration may be of administering the composition according to one embodiment in an amount of 0.1 mg to 1,000 mg per individual per day, for example, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg. However, the dosage may vary depending on factors such as the formulation method, method of administration, patient's age, body weight, gender, pathological condition, food, time of administration, route of administration, excretion rate, and response sensitivity, and a person skilled in the art may appropriately adjust the dosage by considering these factors. The frequency of administration may be once a day or two or more times within the range of clinically acceptable side effects, and the administration site may be one or two or more sites, and the total duration of administration may be from 1 to 30 days per treatment, administered daily or at intervals of 2 to 5 days. If necessary, the same treatment may be repeated after the appropriate time. For animals other than humans, the dosage may be the same as that for humans per kg, or an amount calculated by converting the above dosage based on, for example, the ratio of organ (e.g., heart) volume between the target animal and humans (e.g., average value). Effects of the invention

[0053] A composition according to one aspect has an excellent skin condition improvement effect by inducing a balance of microbiota within the skin through optimizing the content of glycerol and disaccharides. Brief explanation of the drawing

[0054] Figure 1 is a figure showing the average voltage (Mv) measured after treatment with a prebiotic composition of one aspect in a Staphylococcus epidermidis culture medium. Figure 2 is the result of confirming the bacterial flora in the skin based on Staphylococcus epidermidis after treatment with a skin prebiotic composition of one aspect. Figure 3 shows the results of confirming the acne improvement effect after treatment with a skin prebiotic composition of one aspect. Figure 4 is the result of confirming the effect of reducing skin sebum after treatment with a skin prebiotic composition of one aspect. Specific details for implementing the invention

[0055] Preferred embodiments are presented below to aid in understanding the present invention. However, the following embodiments are provided merely to facilitate a better understanding of the invention, and the scope of the invention is not limited by the following embodiments.

[0057] Experimental Example 1. Identification of sugars that induce balance of skin microbiota

[0058] In this experimental example, Staphylococcus epidermidis ( Staphylococcus epidermidis While inducing the growth of ) the acne bacteria Cutibacterium acnes ( Cutibacterium acnes We intended to identify sugars that inhibit the growth of ).

[0059] monosaccharides Fungal species D(+) glucose β-D(-) Fructos D(+) galactose D(+) mannose D(+) Xylose D(+) Arabinos D(-) Ribos Sorbos Ramnos Cutibacterium acnes O O O O X X O X X Staphylococcus epidermidis O O O O X X X X X

[0061] saccharose Fungal species Maltos α-lactose Melibios Sucrose D(+) Trehalose D(+) Turanus Cellobios Cutibacterium acnes Δ X X Δ Δ - X Staphylococcus epidermidis O O X O X Δ X

[0063] trisaccharides sugar alcohol polysaccharides Fungal species D(+) Meletos Raffinos D-Mannitol xylitol Erythritol Sorbitol Inositol starch Cutibacterium acnes Δ X Δ - Δ Δ Δ X Staphylococcus epidermidis X X X X X X X X

[0065] O: Growth promotion, X: Growth inhibition, Δ: Growth maintenance

[0066] As a result, as shown in Tables 1 to 3 above, it was confirmed that disaccharides induced the growth of Staphylococcus epidermidis while maintaining or inhibiting the growth of Cutibacterium acnes.

[0068] Experimental Example 2. Measurement of Microcurrent Generation by Skin Prebiotics

[0069] In this experimental example, a skin prebiotic composition was supplied into a culture medium of Staphylococcus epidermidis, and whether microcurrent was generated was measured. In this experimental example, purified water was used as a control.

[0070] As a result, as shown in Figure 1, it was confirmed that the skin prebiotic composition generates microcurrents in the culture medium of Staphylococcus epidermidis.

[0072] Experimental Example 3. Measurement of the relative abundance of bacterial strains in the skin using skin prebiotics

[0073] In this experimental example, a skin prebiotic composition containing glycerol and disaccharides was prepared, and Staphylococcus epidermidis ( S. epidermidis Based on ), Cutibacterium acnes ( C. acnes ) and Staphilococcus aureus( S. aures The relative abundance of ) was measured.

[0074] Specifically, glycerol, lactose, and sucrose were added to a solvent and mixed according to the content and ratio of the raw materials in Table 4 below, and then stirred to prepare a skin prebiotic composition. As a result, skin prebiotic compositions with different ratios of each mixed raw material (Examples 1 to 3, Comparative Examples 1 and 2) were obtained.

[0075] Ingredients (based on 100g total aqueous solution) Example 1 Example 2 Example 3 Comparative Example 1 Comparative Example 2 Comparative Example 3 Glycerol 2.06g 1.37g 0.69g 0.12g 1.12g 2.06 Lactose 0.03g 0.02g 0.01g 1g 0.5g 0.01 Sucrose 0.03g 0.02g 0.01g 1g 0.5g 0.01 Glycerol:Lactose:Sucrose weight ratio 69:1:1 69:1:1 69:1:1 0.12:1:1 2.24:1:1 206:1:1 Glycerol:disaccharide weight ratio 34.33:1 34.25:1 34.5:1 0.06:1 1.12:1 103:1 S. epidermidis Preparation S. aureus Relative abundance of 0.5 0.54 0.57 1.1 1 0.9 S. epidermidis Preparation C. acnes Relative abundance of 0.03 0.05 0.08 0.35 0.3 0.24

[0077] Subsequently, DNA was extracted from the co-cultures of S. aures, S. epidermidis, and C. acnes containing the compositions of Examples 1 to 3 and Comparisons 1 to 3 using the QIAamp PowerFecal Pro DNA Kit (Qiagen). The DNA was quantified using NanoDrop (NanoDrop One, ThermoFisher Scientific, USA) and Qubit (Qubit Fluorometer 4.0, ThermoFisher Scientific, USA), and then frozen until the experiment. The Qubit reagent used was the dsDNA Quantification Assay Kits (ThermoFisher Scientific, USA). Subsequently, qPCR was performed under the conditions shown in Tables 5 to 7 below. Table 5 shows the primer information, and Tables 6 and 7 show the qPCR reaction conditions. qPCR was performed using the CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA).

[0078] Target Primer Name Sequence (5' to 3') Length (mer) Annealing V5 785F GGATTAGATACCCTGGTA 18 58 V5 907R CCGTCAATTCMTTTRAGTTT 20 S. aureus greA_F CCAGGTGATGAAGAGGAAAGTT 22 60 S. aureus greA_R CCATTAGGTAGTGGAACACGAA 22 S. epidermidis AD_F TTATGGKTGGATCGTGACTG 20 60 S. epidermidis AD_R GTTGGAATCTCAATCGCCAC 20 C. acnes NUDIX_F GCGAGGCCMGAGAAGAAAC 19 64 C. acnes NUDIX_R GTAGACCRCACACCGGATGC 20

[0080] Reagent Volume (uL) note Template (0.0 5ng) X Set to add 0.05 ng to 1 rxn Primer Forward (10 pmole) 1 - Primer Reverse (10 pmole) 1 - SYBR 10 (QuantiSpeed ​​SYBR No-Rox Kit, PhileKorea, Republic of Korea) DW 8 - X (UltraPure DNase / RNase-Free Distilled Water, ThermoFisher Scientific, USA) Total 20 -

[0082] Step Stage Temperature Time note - Pre-Denature 95℃ 10 min - ThermoCycling Denture 95℃ 10 sec 40 cycles Annealing Primer Tm 15 sec Extension 72℃ 15 sec Melting Curve Denture 95℃ 15 sec - Cooling to Tm 65℃ 5 sec - Gradual Denture Up to 95℃ - Raise by 0.5℃ and capture

[0084] Subsequently, Ct values ​​were measured using V5 primers to quantify all microorganisms present in each sample, and Ct values ​​were measured using greA, AD, and NUDIX primers to quantify target microorganisms. The Ct values ​​of each sample were converted into expression values, and the greA, AD, and NUDIX expression values ​​were normalized based on the V5 expression values ​​of each sample. By unifying the amount of all microorganisms in the sample through V5, the data was corrected to allow for a relative comparison of the amount of target microorganisms present in other samples. The expression value of the S. epidermidis sample was fixed at 1, and the ratio of the expression values ​​of the remaining groups to this value was calculated to indicate the relative abundance of each microorganism. The results are shown in Table 8 and Figure 2.

[0085] Glycerin / Lactose / Sucrose content (Based on a total of 100 g of aqueous solution) Relative abundance (based on S. epidermidis) S. epidermidis S. aureus C. acnes control group 1.00 1.26 0.46 Comparative Example 1 1.00 1.10 0.35 Comparative Example 2 1.00 1.00 0.30 Example 1 1.00 0.50 0.03 Example 2 1.00 0.54 0.05 Example 3 1.00 0.57 0.08

[0087] As a result, as shown in Table 8 and Figure 2, it was confirmed that the relative abundance of Staphylococcus epidermidis, a skin beneficial bacterium, in Examples 1 to 3 was significantly increased compared to the comparative examples.

[0088] Synthesizing the above results, the skin prebiotic compositions according to Examples 1 to 3 contain glycerol and disaccharides in an appropriate weight ratio to induce the growth of Staphylococcus epidermidis while inhibiting the growth of Cutibacterium acnes, thereby increasing the relative abundance of Staphylococcus epidermidis in the skin and inducing a balance of the skin's microbiota. Furthermore, it was confirmed that the balance of the skin's microbiota appropriately induces the growth of Staphylococcus epidermidis to generate microcurrents, through which the growth of Cutibacterium acnes can be inhibited.

[0090] Experimental Example 4. Confirmation of the acne-improving effect of skin prebiotic products

[0091] In this experimental example, the acne-improving effect of the skin prebiotic product was confirmed. Specifically, the skin prebiotic composition of Example 1 was applied to subjects with acne-prone skin, and the skin was visually evaluated after 4 weeks.

[0092] As a result, as shown in Figure 3, it was confirmed that the number of open and closed comedones in individuals with acne-prone skin was significantly reduced.

[0094] Experimental Example 5. Confirmation of the sebum-reducing effect of skin prebiotic products

[0095] In this experimental example, the effect of the skin prebiotic composition of Example 1 on skin sebum was confirmed. Specifically, the amount of skin sebum (%) was measured after 4 weeks of applying the product to subjects with acne-prone skin.

[0096] As a result, as shown in Figure 4, it was confirmed that the amount of skin sebum in individuals with acne-prone skin was significantly reduced.

[0098] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical spirit or essential features of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.

Claims

Claim 1 A skin prebiotic composition comprising glycerol, lactose, and sucrose in a weight ratio of 50 to 100 : 1 to 5 : 1 to 5. Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 A skin prebiotic composition according to claim 1, wherein the composition induces a balance of skin flora. Claim 6 In claim 5, the balance of the microbiota within the skin is Staphylococcus epidermidis ( Staphylococcus epidermidis Induction of growth of ) and Cutibacterium acnes ( Cutibacterium acnes A skin prebiotic composition that inhibits the growth of ). Claim 7 A skin prebiotic composition according to claim 1, wherein the composition is for improving skin condition. Claim 8 A skin prebiotic composition according to claim 7, wherein the improvement of the skin condition is improvement of acne, improvement of sebum secretion, or a combination thereof. Claim 9 A cosmetic composition comprising the skin prebiotic composition of claim 1. Claim 10 A topical skin composition comprising the skin prebiotic composition of claim 1. Claim 11 A pharmaceutical composition for the prevention or treatment of a disease associated with increased sebum secretion comprising the skin prebiotic composition of claim 1, wherein the disease associated with increased sebum secretion is acne, seborrheic dermatitis, or folliculitis.

Citation Information

Patent Citations

  • Use of sugar and glycerol combinations for prebiotic benefits

    JP2023516922A